• 最好不要阅读此帖,有毒!看了头晕
  • 福利!24寸免充气蜂窝轮胎,要买的话,免费
  • 好几年没有来论坛了,新老朋友大家好
  • 四月二日,遇难日!
  • 淘小铺开张了!!
  • 观众喜爱的影视剧100部回顾
查看: 9909|回复: 4

[分享] 加拿大准备进行的脊髓损伤试验

[复制链接]

注册会员

注册时间
2009-10-3
损伤时间
2009
损伤原因
车祸
损伤位置
t10
损伤情况
不完全
性别
居住地
湖北
体验信用
0
发表于 2011-12-6 16:32:44 | 显示全部楼层 |阅读模式

论坛版权声明
  1.用户从本论坛的服务中获得的信息,未经本论坛许可,不得任意复制或转载。。
  2.本论坛所有内容仅代表作者自己的立场和观点,与本论坛无关。

注册会员

注册时间
2011-9-22
损伤时间
2009.04
损伤原因
坠落
损伤位置
T10
损伤情况
完全性
性别
居住地
陕西渭南
体验信用
0

爱我中华天平座勋章

发表于 2011-12-6 17:51:12 | 显示全部楼层
看不懂也???

回复 支持 反对

使用道具 举报

注册会员

注册时间
2011-11-10
损伤时间
2008年9月26
损伤原因
脊髓硬脊膜动静脉瘘
损伤位置
胸8
损伤情况
非完全性
性别
居住地
青岛
体验信用
0
发表于 2011-12-6 17:57:51 | 显示全部楼层
我把整个网页文字复制下来有点乱,没办法为给我未注册好友在手机上看(游客身份无法看图片等链接)


学习去评估安全性、耐受性和未确立最大耐受剂量的中枢模式Generator-activating Tritherapy(SPINALON)在脊柱Cord-injured病人
This study is not yet open for participant recruitment.本研究为参与者未开放招聘。
Verified on November 2011证实2011年11月by Nordic Life Science Pipeline Inc.北欧生命科学公司的管道。


First Received on November 25, 2011. 第一次收到2011年11月25日。Last Updated on November 30, 2011最后一次更新2011年11月30日History of Changes历史的变化
Sponsor:赞助: Nordic Life Science Pipeline Inc.生命科学管道公司北欧
Collaborator:合作者: Department of Defense国防部的

Information provided by (Responsible Party):所提供的资料(责任方): Nordic Life Science Pipeline Inc.生命科学管道公司北欧
ClinicalTrials.ClinicalTrials。gov Identifier:州长标识符: NCT01484184NCT01484184

Purpose目的
As a first-in-class (Central Pattern Generator or CPG activator) approach, this tritherapy candidate called SPINALON has been identified and is currently under development for its capacity to temporarily induce episodes of involuntary locomotor movements. 作为一个first-in-class(中枢模式发生器或中央活化剂)方法,该候选人称为SPINALON tritherapy已被确认和正在发展其能力暂时诱导发作的不由自主的运动运动。The primary objective of this Phase I/IIa study is to assess safety and tolerability of a single escalating dose of SPINALON (levodopa + carbidopa + buspirone) in chronic spinal cord-injured patients. 这一阶段的主要目的是研究I /协会来评估一个单一的安全性和耐受性升级剂量的SPINALON(左旋多巴+卡比多巴+ buspirone)在慢性脊髓cord-injured病人。As a secondary objective, preliminary evidence of efficacy will also be sought.作为一个次要目标,初步证明的效能也会被追求的目标。



Condition条件 Intervention干预 Phase阶段
Spinal Cord Injury脊髓损伤
Drug: SPINALON (buspirone + levodopa + cardidopa)药物:SPINALON(buspirone +左旋多巴+ cardidopa)
Phase I期
Phase II二期



Study Type:研究类型: Interventional介入
Study Design:研究设计: Allocation:Randomized配置:随机
EndpointClassification:Safety/EfficacyStudyEndpointClassification:安全/ EfficacyStudy
InterventionModel:FactorialAssignmentInterventionModel:FactorialAssignment
Masking:DoubleBlind(Subject,Investigator)掩蔽:DoubleBlind(主题,调查员)
PrimaryPurpose:TreatmentPrimaryPurpose:治疗
Official Title:正式标题: Tri-therapy (SPINALON)-Elicited Spinal Locomotor Network Activation: Phase I-IIa Clinical Trial in Spinal Cord-injured PatientsTri-therapy(SPINALON)-Elicited脊柱运动网络启动:临床试验阶段I-IIa脊柱Cord-injured病人


Resource links provided by NLM:资源环节提供的中华:


MedlinePlus医疗在线related topics:相关的话题:SpinalCordInjuriesSpinalCordInjuries
Drug Information药品信息available for:可为:Levodopa左旋多巴BuspironehydrochlorideBuspironehydrochlorideBuspironeBuspirone
U.S. FDA Resources美国食品及药物管理局(FDA)资源



Further study details as provided by Nordic Life Science Pipeline Inc.:进一步研究提供细节的北欧生命科学管道有限公司:


Primary Outcome Measures:主要结果测量:
Heart rate [ Time Frame: Steadily during 4 hours post-single administration vs Pre-administration ] [ Designated as safety issue: Yes ]心率[时间框架:在4小时post-single稳定管理与Pre-administration][指定为安全问题:是的)
Heart rate as a safety measure will be measured as beats per minute during 4 hours post-administration during the only administration心率安全措施,以每分钟搏动post-administration在4个小时在唯一的管理


Tolerability of common AEs [ Time Frame: During 4 hours post-single administration vs pre-administration ] [ Designated as safety issue: No ]常见的耐受性AEs[时间框架:在4小时post-single管理与pre-administration][指定为安全问题:没有)
Frequent AEs such as nausea and hypotention will be specifically measured to assess tolerability and maximum tolerated dose. 频繁的AEs如恶心和降压将具体测量来评估和最大耐受剂量耐受性。No more than 20% of subjects experiencing nausea with > grade 2 severity. 不超过20%的受试者经历与> 2级恶心症状。Dose schedule without ≥ grade 3 hypotension. 计划没有≥3级剂量低血压。No potentiation of other AEs possibly found for each molecule administered separately没有其他的potentiation AEs可能发现每个水分子分业管理


Pharmacokinetics [ Time Frame: 15, 30, 60, 120 and 240 min post-administration vs pre-administration ] [ Designated as safety issue: Yes ]药代动力学[时间框架:15、30、60、120和240分钟post-administration对pre-administration][指定为安全问题:是的)
Blood samples will be repeatedly obtained post-administration on the day of testing. 血液样本将post-administration反复的日子得到测试。HPLC analysis will be conducted to assess typical PK values (Cmax, Tmax, AUC) in order to determine whether or not the known PK profile of each active molecule (levodopa, carbidopa, buspirone) is changed once administered concomitantly (SPINALON)高效液相色谱分析,将进行评估的典型PK值(Cmax,Tmax,AUC),以决定是否已知PK剖面各有效分子(左旋多巴,卡比多巴,buspirone)是经过一次变化,同时管理(SPINALON)


Blood pressure [ Time Frame: During 4 hours post-single administration vs pre-administration ] [ Designated as safety issue: Yes ]血压[时间框架:在4小时post-single管理与pre-administration][指定为安全问题:是的)
Systolic and diastolic blood pressure values as a safety measure will be measured as mmHg during 4 hours收缩期和舒张期血压值为一个安全措施将以毫米汞柱在4个小时


Respiration rate [ Time Frame: During 4 hours post-single administration vs pre-administration ] [ Designated as safety issue: Yes ]呼吸速率(4小时的时间框架:在管理与post-single pre-administration][指定为安全问题:是的)
Respiration rate as number per minute will be measured as a safety issue during 4 hours post-administration compared with baseline value pre-administration on the day of testing为每分钟呼吸速率数量将检测作为一个安全问题在4小时post-administration pre-administration基线值相比,在这一天的测试


Oxygen saturation [ Time Frame: During 4 hours post-single administration vs. pre-administration ] [ Designated as safety issue: Yes ]氧饱和度(4小时的时间框架:在post-single管理vs. pre-administration][指定为安全问题:是的)
Oxygen saturation measured as CO2 level and O2 level in pourcentage will be measured on the day of testing during 4 hours post-administration compared with baseline level (pre-administration)血氧饱和度测量CO2浓度和氧气水平衡量pourcentage当天在4小时的测试post-administration基线水平相比(pre-administration)


Temperature [ Time Frame: During 4 hours post-single administration vs. pre-administration ] [ Designated as safety issue: Yes ]温度[时间框架:在4小时post-single管理vs. pre-administration][指定为安全问题:是的)
Temperature measured in degrees Celsius will be measured during 4 hours post-administration on the day of testing compared with baseline value (pre-administration)在摄氏度测量温度将在4小时post-administration测量在一天的测试与基线相比价值(pre-administration)


Change in hematology and biochemistry laboratory parameters [ Time Frame: Once at 4 hours post-single administration vs pre-administration ] [ Designated as safety issue: Yes ]血液学及生化实验室改变参数[时间框架:曾在4小时post-single管理与pre-administration][指定为安全问题:是的)
Blood samples at 4 hours post-administration will be analyzed for standard hematology (CBC) and biochemistry (liver and kidney markers) values and compared with baseline values (medical exam day sample).在4小时的血液样本进行分析post-administration标准血液学(CBC)和生物化学(肝、肾标记值)和比较的基线值(医学考试那天样品)。




Secondary Outcome Measures:其次措施:
Occurrence of rhythmic leg EMGs [ Time Frame: During 2 hours post-administration vs pre-administration ] [ Designated as safety issue: No ]发生的有节奏的腿EMGs[时间框架:在2小时post-administration对pre-administration][指定为安全问题:没有)
EMG activities of leg muscles will be measured with surface elecrodes during 2 hours post-administration on the day of testing compared with baseline values pre-administration. 肌电图(EMG)活动的腿肌肉会与表面elecrodes测量在2小时post-administration在一天的测试pre-administration基线值相比。Possible occurrence of involuntary rhythmic and bilateral movements assessed quantitatively will be sought.可能发生的无意识动作节奏和双边定量评估将会寻求。



Estimated Enrollment:估计登记: 5151
Study Start Date:研究开始日期: May 20122012年5月
Estimated Study Completion Date:估计研究的竣工日期: April 20142014年4月
Estimated Primary Completion Date:估计基本竣工日期: December 2013 (Final data collection date for primary outcome measure)2013年12月(最终数据采集日期为主要转归指标)

Arms武器 Assigned Interventions指定的干预
buspirone or levodopa/carbidopa: Active Comparatorbuspirone或左旋多巴/卡比多巴:活跃的对照
Another 2-arm design will be tested composed of 16 subjects receiving drug A or drug B at MTD dose of the combined study drug as identified in the previous 2-arm groups.另一个2-arm设计将测试对象组成的药物或16接受药物在未确立最大耐受剂量剂量的结合中研究药物前2-arm组。
Intervention: Drug: SPINALON (buspirone + levodopa + cardidopa)干预:药物:SPINALON(buspirone +左旋多巴+ cardidopa) Drug: SPINALON (buspirone + levodopa + cardidopa)药物:SPINALON(buspirone +左旋多巴+ cardidopa)
The proposed study is a combination of 1 and 2-arm designs. 该研究是一个相结合的1和2-arm设计。First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. 首先,2-arm设计将用,第一个臂收到由3科的最低剂量药物的研究,第二次臂主体由1注射对照剂。This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. 这2-arm设计将连续重复(不同时)与增加剂量的SPINALON,只要剂量有良好的耐受性。Six (6) groups are expected to be tested with this 2-arm design.六(6)集团预计将这2-arm进行设计。This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.这将是紧随其后的是一个2-arm由1组与安慰剂组1和1主体接受更大的组织(10科),将得到SPINALON未确立最大耐受剂量所指定前2-arm组。
Other Names:其他的名字:
Apo-Buspirone 10 mg tablets (DIN 02211076)Apo-Buspirone 10毫克片剂(DIN 02211076)
Sinemet 100/25 mg tablets (DIN 00513997)Sinemet 100/25毫克片剂(DIN 00513997)

Placebo: Placebo Comparator安慰剂。安慰剂对照
First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of SPINALON, the second arm being composed of 1 subject receiving a placebo. 首先,2-arm设计将用,第一个臂收到由3科的最低剂量的SPINALON,第二个臂主体由1注射对照剂。This 2-arm design will be repeated consecutively with increasing doses, as long as the dose is well tolerated. 这2-arm设计将增加重复连续剂量,只要剂量有良好的耐受性。Six (6) groups are expected to be tested with this 2-arm design.六(6)集团预计将这2-arm进行设计。
Intervention: Drug: SPINALON (buspirone + levodopa + cardidopa)干预:药物:SPINALON(buspirone +左旋多巴+ cardidopa) Drug: SPINALON (buspirone + levodopa + cardidopa)药物:SPINALON(buspirone +左旋多巴+ cardidopa)
The proposed study is a combination of 1 and 2-arm designs. 该研究是一个相结合的1和2-arm设计。First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. 首先,2-arm设计将用,第一个臂收到由3科的最低剂量药物的研究,第二次臂主体由1注射对照剂。This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. 这2-arm设计将连续重复(不同时)与增加剂量的SPINALON,只要剂量有良好的耐受性。Six (6) groups are expected to be tested with this 2-arm design.六(6)集团预计将这2-arm进行设计。This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.这将是紧随其后的是一个2-arm由1组与安慰剂组1和1主体接受更大的组织(10科),将得到SPINALON未确立最大耐受剂量所指定前2-arm组。
Other Names:其他的名字:
Apo-Buspirone 10 mg tablets (DIN 02211076)Apo-Buspirone 10毫克片剂(DIN 02211076)
Sinemet 100/25 mg tablets (DIN 00513997)Sinemet 100/25毫克片剂(DIN 00513997)



Detailed Description:详细描述:
Spinal cord injury (SCI) is generally considered as an irreversible condition for which no curative treatment has yet been found. 脊髓损伤(SCI)通常会被看作是一个不可逆转的条件没有唯一有效的治疗方式,尚未发现。A recent study sponsored by the Christopher & Dana Reeve Foundation revealed an incidence ranging between 40 and 60 cases per million population and a prevalence estimated to be several times greater (new data: 1,275,000 cases) than previously reported(previous data: 200,000 cases).最近的一项研究由克里斯托弗和戴娜·里维基础包括了一个发生在40至60例每百万人口和发生率估计是几倍(新数据:1275000例)超过了以往的报道(之前的数据:200000例)。

SPINALON (levodopa + carbidopa + buspirone) was discovered by Dr. Guertin and colleagues as a drug treatment candidate that can acutely elicit temporarily (lasting approximately 30-60 minutes) episodes of CPG activity and corresponding powerful weight-bearing hindlimb stepping in completely SCI subjects (preclinical efficacy data obtained from mice and turtles completely spinal cord transected thoracically).SPINALON(左旋多巴+卡比多巴+ buspirone)发现Guertin博士和同事间的候选药物治疗能引发强烈暂时(持续大约30 - 60分钟)的事件活动和相应的强大中央承重hindlimb踩到完全科学科目(临床疗效和海龟从老鼠身上得到的数据完全脊髓transected thoracically)。

As such, SPINALON is currently being developed to become a chronic treatment (physical activity-based approach driven pharmacologically) against the multiple health problems or so-called 'secondary complications' associated specifically with the lack of physical activity (sarcopenia, osteoporosis, cardiovascular problems, dyslipidemia, obesity, type II diabetes, anemia, immune system deficiency, deep vein cloth, depression, etc.).这样,SPINALON正在发展成为一种慢性治疗(物理作业的方��驱使药物)对多种健康问题或者所谓“次要并发症的相关具体缺乏体力活动的sarcopenia、骨质疏松、心血管疾病、肥胖、高血脂、二型糖尿病、贫血、免疫系统的不足之处,深静脉布、抑郁等)。

This study is a randomized, placebo-controlled, double-blind, single dose escalation study with fifty-one (51) patients who will receive either placebo capsules(starch) or capsules with buspirone only, levodopa/carbidopa only or buspirone/levodopa/carbidopa (SPINALON).本研究是一项随机、安慰剂对照、双盲、单剂量升级研究(51)患者51名将得到安慰剂(淀粉)或胶囊胶囊与buspirone,只有唯一或buspirone左旋多巴/卡比多巴/左旋多巴/卡比多巴(SPINALON)。

Eligibility资格


Ages Eligible for Study:研究年龄资格: 18 Years to 65 Years18年至65年
Genders Eligible for Study:性别研究资格: Both两
Accepts Healthy Volunteers:健康志愿者接受: No没有

Criteria标准
Inclusion Criteria:入选标准:

Clinical diagnosis of complete or motor-complete SCI (ASIA-A, ASIA-B)临床诊断完全或motor-complete SCI(ASIA-A,ASIA-B)
Chronically injured (at least 3 months post-injury)长期受伤(至少3个月post-injury)
Paraplegic (within T1-T12) or tetraplegic (within C3-C8)脊髓损伤(在T1-T12)或tetraplegic(在C3-C8)
In relatively good health condition (no significant bed sore, urinary tract infection)比较好的健康状况(无显著的床上痛,尿路感染)
18-65 years of age18 - 65岁
Men and women男人和女人
Exclusion Criteria:排除标准::

With unclear diagnosis诊断不明
Displayed a form of involuntary rhythmic leg muscle activity (restless leg syndrome, spontaneous activity in supine position, etc.) in the last 3 months prior to this study.展示了一种形式的无意识有节奏的腿部肌肉活动(下肢不适综合症,自发活动在仰卧位,等。在最后对该研究的前三个月。
Acute or subacute stage (within 1 day and 3 months post-injury)急性或亚急性阶段(1天、3个月之内post-injury)
Non-traumatic (e.g., multiple sclerosis, syringomyelia, spinal tumor,etc.)首(如多发性硬化、脊髓脊柱肿瘤,等等。)
Are given monoamine oxidase (MAO) inhibitors (two weeks prior and after Spinalon administration)给出了单胺氧化酶(毛)抑制剂(前两周后,Spinalon管理)
Had seizures有癫痫发作
Had tumor(s) (malignant or non-malignant) or in situ carcinoma in the last five (5) years肿瘤(s)(恶性或至非惡性)或原位癌在过去五(5)年呢
Allergic or hypersensitive to buspirone, levodopa or carbidopa过敏或敏感,buspirone,左旋多巴或卡比多巴
Can not take sympathomimetic amines (e.g., epinephrine, pseudoephedrine)不能把sympathomimetic胺(例如,肾上腺素、伪麻黄碱)
Currently suffering of heart problems, blood related diseases, endocrine disease, liver disease, lung disease, or kidney disease目前遭受心脏病、血液相关疾病、内分泌疾病、肝脏疾病、肺病、或肾脏疾病
Receiving antihypertensive drugs接受抗高血压药物
Receiving tricyclic antidepressant接收三环类抗抑郁
Receiving dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone)接收多巴胺D2受体拮抗剂(例如,吩噻嗪,butyrophenones、利培酮)
Receiving phenytoin and papaverine接收phenytoin和papaverine
With glaucoma青光眼
With psychiatric or mental disorder(s)有精神或心理障碍(s)
Had gastrointestinal ulcer(s) in the last five (5) years有溃疡(s)在过去的五(5)年呢
Pregnant or lactating woman (all women between 18 and 50 year-old not yet confirmed as pregnant, will be tested (urine test - TestPak Plus, Abbott Laboratories) on medical exam-day due to the teratogenic potential of levodopa/carbidopa.女人(孕妇或哺乳期妇女所有女人在18至50岁��未确认怀孕期间,将测试(尿检验——TestPak另外,雅培公司)对医疗exam-day由于左旋多巴/卡比多巴致畸的潜力。
Children (younger than 18 year-old) or elderly (older than 65 year-old)儿童(小于18岁)或老年人(大于65岁的)
Contacts and Locations接触和地点

Please refer to this study by its ClinicalTrials.请参阅本研究以其ClinicalTrials。gov identifier: NCT01484184州长标识符:NCT01484184


Contacts接触
Contact: Hugues Barbeau, Ph.D.请联系:< 0 }。Hugues Barbeau,博士。 450-468-7040450-468-7040 hugues.barbeau@mcgill.cahugues.barbeau@mcgill.ca
Contact: Mohan Radhakrishna, MD接触:Radhakrishna不但获得 514-934-1934 ext 44185514-934-1934分机44185 mohan.radhakrishna@mcgill.camohan.radhakrishna@mcgill.ca


Locations地点
Canada, Quebec加拿大魁北克,
McGill University Health Centre (Montreal General Hospital)麦吉尔大学健康中心(蒙特利尔综合医院)
Montreal, Quebec, Canada, H3G 1A4魁北克的蒙特利尔、加拿大、H3G 1 A4

Sponsors and Collaborators赞助商和合作者
Nordic Life Science Pipeline Inc.生命科学管道公司北欧
Department of Defense国防部的
Investigators调查人员
Study Director:研究主任: Pierre Guertin, Ph.D.皮埃尔Guertin,博士。 Nordic Life Science Pipeline/Université Laval北欧生命科学/大学管道颗粒

More Information更多的信息

Additional Information:额外的信息:
Sponsor's website赞助商的网站
Support of funding organization资金支持的组织

Publications:论文:
Guertin PA, Ung RV, Rouleau P, Steuer I. Effects on locomotion, muscle, bone, and blood induced by a combination therapy eliciting weight-bearing stepping in nonassisted spinal cord-transected mice. Neurorehabil Neural Repair. 2011 Mar-Apr;25(3):234-42. Epub 2010 Oct 15.Guertin啪,Ung房车、Rouleau P,即影响Steuer运动,肌肉、骨骼、血液诱导引起一个联合治疗脊柱cord-transected承重踩到nonassisted老鼠。Neurorehabil神经修复。2011年3 - 4月;25(3):234 -。10月15 2010年。
Guertin PA, Ung RV, Rouleau P. Oral administration of a tri-therapy for central pattern generator activation in paraplegic mice: proof-of-concept of efficacy. Biotechnol J. 2010 Apr;5(4):421-6.Guertin啪,Ung房车、Rouleau口服给药一页tri-therapy中枢模式发生器为脊髓损伤小鼠激活:耕耘的效能。Biotechnol j . 2010年4月,5(4):421 -。
Guertin PA. The mammalian central pattern generator for locomotion. Brain Res Rev. 2009 Dec 11;62(1):45-56. Epub 2009 Aug 29. Review.Guertin通道。哺乳动物中枢模式发生器,运动方式。2009年11月《脑研究,62(1):45-56。2009年8月29日。审查。
Lapointe NP, Rouleau P, Ung RV, Guertin PA. Specific role of dopamine D1 receptors in spinal network activation and rhythmic movement induction in vertebrates. J Physiol. 2009 Apr 1;587(Pt 7):1499-511. Epub 2009 Feb 9.Lapointe NP,Rouleau磷、Ung房车、Guertin通道。D1受体的特殊角色多巴胺在脊柱网络激活和节奏性运动诱导在脊椎动物。[J].中国中西医结合杂志。2009年4月1;587(Pt 7):1499 - 511。2月9日2009年。
Lapointe NP, Guertin PA. Synergistic effects of D1/5 and 5-HT1A/7 receptor agonists on locomotor movement induction in complete spinal cord-transected mice. J Neurophysiol. 2008 Jul;100(1):160-8. Epub 2008 May 14.Lapointe NP,Guertin通道。D1/5协同效应和5-HT1A / 7的受体在运动运动的诱导完全脊髓cord-transected老鼠。J Neurophysiol。2008年7月,100(1):160 - 8。5月14日2008年。
Landry ES, Lapointe NP, Rouillard C, Levesque D, Hedlund PB, Guertin PA. Contribution of spinal 5-HT1A and 5-HT7 receptors to locomotor-like movement induced by 8-OH-DPAT in spinal cord-transected mice. Eur J Neurosci. 2006 Jul;24(2):535-46. Epub 2006 Jul 12.兰德里,是的,Lapointe NP,Rouillard C,Levesque D,Hedlund铅、Guertin通道。脊柱5-HT1A贡献和5-HT7受体如何locomotor-like诱导脊柱运动8-OH-DPAT cord-transected老鼠。> .《自然神经科学》。2006 . 7欧元;24(2):535 - 46页。7月12 2006年。

Responsible Party:负责任的聚会。 Nordic Life Science Pipeline Inc.生命科学管道公司北欧
ClinicalTrials.ClinicalTrials。gov Identifier:州长标识符: NCT01484184NCT01484184 History of Changes历史的变化
Other Study ID Numbers:其它研究ID号: SPIN-01SPIN-01
Study First Received:书房先收到: November 25, 201111月25日,
Last Updated:最后一次更新: November 30, 20112011年11月30日,
Health Authority:卫生主管机关定之。 Canada: Health Canada加拿大:加拿大健康

Keywords provided by Nordic Life Science Pipeline Inc.:关键词提供管道公司北欧生命科学:
Completely paralyzed完全瘫痪
Chronically injured长期受伤的
Comorbid problems伴发的问题
Central Pattern Generator中枢模式发生器
Locomotion运动
Secondary complications次要并发症
Activity-based training作业培训
Treadmill training跑步训练



Additional relevant MeSH terms:另外有关网格条件:
Spinal Cord Injuries脊髓损伤
Spinal Cord Diseases脊髓疾病
Central Nervous System Diseases中枢神经系统疾病
Nervous System Diseases神经系统疾病
Trauma, Nervous System创伤、神经系统
Wounds and Injuries创伤和损伤
BuspironeBuspirone
Levodopa左旋多巴
Serotonin Receptor Agonists5 -羟色胺受体激动剂
Serotonin Agents5 -羟色胺剂
Neurotransmitter Agents神经递质剂
Molecular Mechanisms of Pharmacological Action分子机制的药理作用
Pharmacologic Actions药物的行为
Physiological Effects of Drugs生理药物效应
Anti-Anxiety Agents抗焦虑药物
Tranquilizing Agents镇静药物
Central Nervous System Depressants中枢神经系统镇静剂
Central Nervous System Agents中枢神经系统药物
Therapeutic Uses治疗使用
Psychotropic Drugs精神药品
Antiparkinson AgentsAntiparkinson代理
Anti-Dyskinesia AgentsAnti-Dyskinesia代理
Dopamine Agents多巴胺剂



ClinicalTrials.ClinicalTrials。gov processed this record on December 04, 2011州长这一纪录12月04处理,2011年


Back to top of Main Content回到顶级的主要内容


Contact Help Desk服务台联系
Lister Hill National Center for Biomedical Communications李斯特希尔国家中心为生物医学交流, U.S. National Library of Medicine美国国家医学图书馆,
U.S. National Institutes of Health美国国家健康学会提供, U.S. Department of Health & Human Services美国健康部门和人力服务,
USA.govUSA.gov, Copyright版权, Privacy隐私, Accessibility可及性, Freedom of Information Act的信息自由法案


回复 支持 反对

使用道具 举报

注册会员

注册时间
2011-6-7
损伤时间
1998
损伤原因
车祸
损伤位置
胸12腰0
损伤情况
完全
性别
居住地
浙江
体验信用
0
发表于 2011-12-6 18:29:29 | 显示全部楼层
能看到您发的帖真好

回复 支持 反对

使用道具 举报

注册会员

注册时间
2011-3-13
损伤时间
05 年
损伤原因
摔伤
损伤位置
颈椎C5,C6
损伤情况
非完全性
性别
居住地
柳州市
体验信用
0
发表于 2011-12-6 19:42:48 | 显示全部楼层
希望不再是浮云

回复 支持 反对

使用道具 举报

您需要登录后才可以回帖 登录 | 中文注册   扫一扫,用微信登录

本版积分规则

无觅相关文章插件

快速回复 返回顶部 返回列表